Literature DB >> 20473898

Prospective study of human papillomavirus and risk of cervical adenocarcinoma.

Lisen Arnheim Dahlström1, Nathalie Ylitalo, Karin Sundström, Juni Palmgren, Alexander Ploner, Sandra Eloranta, Carani B Sanjeevi, Sonia Andersson, Thomas Rohan, Joakim Dillner, Hans-Olov Adami, Pär Sparén.   

Abstract

Human papillomaviruses (HPV) are established as a major cause of cervical carcinoma. However, causality inference is dependent on prospective evidence showing that exposure predicts risk for future disease. Such evidence is available for squamous cell carcinoma, but not for cervical adenocarcinoma. We followed a population-based cohort of 994,120 women who participated in cytological screening in Sweden for a median of 6.7 years. Baseline smears from women who developed adenocarcinoma during follow-up (118 women with in situ disease and 164 with invasive disease) and their individually matched controls (1,434 smears) were analyzed for HPV using PCR. Conditional logistic regression was used to estimate odds ratios (OR) of future adenocarcinoma with 95% confidence intervals (CI). Being positive for HPV 16 in the first cytologically normal smear was associated with increased risks for both future adenocarcinoma in situ (OR: 11.0, 95% CI: 2.6-46.8) and invasive adenocarcinoma (OR: 16.0, 95% CI: 3.8-66.7), compared to being negative for HPV 16. Similarly, an HPV 18 positive smear was associated with increased risks for adenocarcinoma in situ (OR: 26.0, 95% CI: 3.5-192) and invasive adenocarcinoma (OR: 28.0, 95% CI: 3.8-206), compared to an HPV 18 negative smear. Being positive for HPV 16/18 in 2 subsequent smears was associated with an infinite risk of both in situ and invasive adenocarcinoma. In conclusion, infections with HPV 16 and 18 are detectable up to at least 14 years before diagnosis of cervical adenocarcinoma. Our data provide prospective evidence that the association of HPV 16/18 with cervical adenocarcinoma is strong and causal.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473898      PMCID: PMC2930102          DOI: 10.1002/ijc.25408

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  23 in total

1.  Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma.

Authors:  E C Pirog; B Kleter; S Olgac; P Bobkiewicz; J Lindeman; W G Quint; R M Richart; C Isacson
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.

Authors:  M Tawfik El-Mansi; K S Cuschieri; R G Morris; A R W Williams
Journal:  Int J Gynecol Cancer       Date:  2006 May-Jun       Impact factor: 3.437

3.  Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

Authors:  Xavier Castellsagué; Mireia Díaz; Silvia de Sanjosé; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; Rosanna W Peeling; Rhoda Ashley; Jennifer S Smith; Peter J F Snijders; Chris J L M Meijer; F Xavier Bosch
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

4.  A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ.

Authors:  N Ylitalo; A Josefsson; M Melbye; P Sörensen; M Frisch; P K Andersen; P Sparén; M Gustafsson; P Magnusson; J Pontén; U Gyllensten; H O Adami
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

5.  International trends in incidence of cervical cancer: II. Squamous-cell carcinoma.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; J Borras; D M Parkin
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

6.  Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus.

Authors:  Anna Söderlund-Strand; Joyce Carlson; Joakim Dillner
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

7.  Screening and adenocarcinoma of the cervix.

Authors:  Peter Sasieni; Alejandra Castanon; Jack Cuzick
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

8.  Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden.

Authors:  Bengt Andrae; Levent Kemetli; Pär Sparén; Lena Silfverdal; Björn Strander; Walter Ryd; Joakim Dillner; Sven Törnberg
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

9.  Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies.

Authors:  Amy Berrington de González; Jane Green
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

10.  Human papillomavirus 16 infection in adenocarcinoma of the cervix.

Authors:  G K Chew; M E Cruickshank; P H Rooney; I D Miller; D E Parkin; G I Murray
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

View more
  19 in total

1.  Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology.

Authors:  Jing Ye; Bei Cheng; Yi-Fan Cheng; Ye-Li Yao; Xing Xie; Wei-Guo Lu; Xiao-Dong Cheng
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

2.  Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.

Authors:  Ying Ma; Andrew Yang; Shiwen Peng; Jin Qiu; Emily Farmer; Chien-Fu Hung; T-C Wu
Journal:  Vaccine       Date:  2017-06-07       Impact factor: 3.641

3.  Interactions Between High- and Low-Risk HPV Types Reduce the Risk of Squamous Cervical Cancer.

Authors:  Karin Sundström; Alexander Ploner; Lisen Arnheim-Dahlström; Sandra Eloranta; Juni Palmgren; Hans-Olov Adami; Nathalie Ylitalo Helm; Pär Sparén; Joakim Dillner
Journal:  J Natl Cancer Inst       Date:  2015-07-09       Impact factor: 13.506

4.  Bereavement Is Associated with an Increased Risk of HPV Infection and Cervical Cancer: An Epidemiological Study in Sweden.

Authors:  Donghao Lu; Karin Sundström; Pär Sparén; Katja Fall; Arvid Sjölander; Joakim Dillner; Nathalie Ylitalo Helm; Hans-Olov Adami; Unnur Valdimarsdóttir; Fang Fang
Journal:  Cancer Res       Date:  2015-12-03       Impact factor: 12.701

Review 5.  Updating the natural history of human papillomavirus and anogenital cancers.

Authors:  Anna-Barbara Moscicki; Mark Schiffman; Ann Burchell; Ginesa Albero; Anna R Giuliano; Marc T Goodman; Susanne K Kjaer; Joel Palefsky
Journal:  Vaccine       Date:  2012-11-20       Impact factor: 3.641

6.  Breast cancer and ductal carcinoma in situ among women with prior squamous or glandular precancer in the cervix: a register-based study.

Authors:  B T Hansen; M Nygård; R S Falk; S Hofvind
Journal:  Br J Cancer       Date:  2012-09-25       Impact factor: 7.640

7.  Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Authors:  Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger
Journal:  Int J Cancer       Date:  2019-05-06       Impact factor: 7.316

8.  Epidemiology of Cervical Adenocarcinoma and Squamous Cell Carcinoma Among Women Living With Human Immunodeficiency Virus Compared With the General Population in the United States.

Authors:  Anne F Rositch; Kimberly Levinson; Gita Suneja; Analise Monterosso; Maria J Schymura; Timothy S McNeel; Marie-Josephe Horner; Eric Engels; Meredith S Shiels
Journal:  Clin Infect Dis       Date:  2022-03-09       Impact factor: 20.999

9.  Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ.

Authors:  Sonia Andersson; Miriam Mints; Erik Wilander
Journal:  Oncol Lett       Date:  2013-05-15       Impact factor: 2.967

10.  Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study.

Authors:  Vitaly Smelov; Tarik Gheit; Karin Sundström; Alexander Ploner; Sandrine McKay-Chopin; Carina Eklund; Massimo Tommasino; Joakim Dillner
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.